

301/LG/SE/NOV/2023/GBSL

November 18, 2023

To,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort, Mumbai – 400 001
Scrip Code : 509079

To,
National Stock Exchange of India Limited,
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
Scrip Symbol : GUFICBIO

Sub.: Intimation of incorporation of Subsidiary Company

Dear Sir/Madam,

This is in continuation to our letter dated August 11, 2023 and August 19, 2023 and pursuant to Regulation 30 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations'), we hereby inform that the Company has incorporated a Subsidiary Company in India namely "**GUFIC PRIME PRIVATE LIMITED**" on November 18, 2023 under Corporate Identification Number: U46497MP2023PTC068618.

The details as required under Regulation 30 of SEBI Listing Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13th July, 2023 is as under:

| Sr. No. | Particulars | Details |
|---------|--|---|
| 1. | Name of the target entity, details in brief such as size, turnover etc. | Name of the Company: Gufic Prime Private Limited ("GPPL"). Authorized Capital: Rs. 15,00,000/- (Rupees Fifteen Lakhs only) Paid up Capital: Rs. 100,000/- (Rupees One Lakh only) Size/Turnover: Not Applicable since GPPL is a newly incorporated Company. |
| 2. | Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group / group companies have any interest in | GPPL is a related party of the Company. |

Regd. Off.: 37, First Floor, Kamala Bhavan II, S. Nityanand Road. Andheri (East). Mumbai - 400 069
Corp. Office : SM House, 1st to 4th Floor, 11 Sahakar Road, Vile Parle (East), Mumbai - 400 057.
Tel.: (91-22) 6726 1000 Fax : (91-22) 6726 1068 Email : info@guficbio.com, Website: www.guficbio.com
Factory: National Highway No. 8, Near GEB Grid, At & PO Kabilpore, Navsari - 396 424, Gujarat, INDIA

| | | |
|-----|--|--|
| | the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length” | Save and except what is mentioned above, the promoter / promoter group are not interested in the said transaction. |
| 3. | Industry to which the entity being acquired belongs | Pharmaceuticals |
| 4. | Objects and effects of acquisition (including but not limited to, reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity); | GPPL shall carry on the business of manufacturing, marketing, distribution and sale of pharmaceutical products. |
| 5. | Brief details of any governmental or regulatory approvals required for the acquisition | Not Applicable |
| 6. | Indicative time period for completion of the acquisition | Not Applicable |
| 7. | Nature of consideration - whether cash consideration or share swap and details of the same | 88% subscription to the equity share capital for cash consideration |
| 8. | Cost of acquisition or the price at which the shares are acquired; | The Cost of subscription of shares would be Rs. 88,000/- (88,000 equity shares of Face Value of Rs. 1/- each) |
| 9. | Percentage of shareholding / control acquired and / or number of shares acquired | 88% |
| 10. | Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief) | GPPL is incorporated on November 18, 2023 and is yet to commence its business operation. |



GUFIC
BIOSCIENCES LIMITED

CIN L24100MH1984PLC033519

Kindly take the same on record.

Thanking You,

For Gufic Biosciences Limited

Ami Shah

Company Secretary & Compliance Officer

Membership No. A39579